Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Protagonist Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Biotech Firms

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. ImmunityBio, Inc. and Protagonist Therapeutics, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, ImmunityBio's SG&A expenses have fluctuated significantly, peaking in 2015 with a staggering 2,262% increase from the previous year. In contrast, Protagonist Therapeutics has maintained a more consistent trajectory, with a steady rise in expenses, culminating in a 79% increase from 2014 to 2023.

ImmunityBio's strategy appears to involve aggressive spending, possibly to fuel rapid growth or innovation, while Protagonist Therapeutics seems to focus on steady, controlled expansion. This divergence in financial strategy highlights the varied approaches companies can take in managing operational costs, each with its own set of risks and rewards.